research on semaglutide is a GLP-1 Receptor Agonist for T2DM and Obesity Semaglutide: Structure and Analogue Design
Description
This marked decrease in appetite may lead to insufficient energy availability for exercise, particularly during moderate to high-intensity workouts
Cell Rep 9 , 661673, doi:10.1016/j.celrep.2014.09.030 (2014)
Make sure to prioritize sleep and rest periods
A clinical trial tested semaglutide in people with mild, moderate, and even severe hepatic impairment
References 1 FosterNCBeckRWMillerKMClementsMARickelsMRDiMeglioLAet al
